Clinical trials: Synucleinopathy
Parkinson's Disease
Study of Parkinson's Early Stage With Deferiprone
The goal of this study is to evaluate the effects of deferiprone, an iron-chelating drug, in patients with Parkinson's disease. Participants will be randomized to receive one of four different dosages of deferiprone or placebo…
- Trial name
- SKY (NCT02728843)
- Testing
- Deferiprone
- Where
- 20 sites in Canada, France and 2 more
- Volunteers
- 140 people
- Sponsor
- ApoPharma
Parkinson's Disease
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
The study had three distinct parts and is described as follows: Part 1: To evaluate the dose conversion from CD-LD ER taken alone or in combination with CD-LD IR to IPX066 in subjects with advanced PD To evaluate the utility of…
- Trial name
- NCT01411137
- Testing
- IPX066
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Impax Laboratories, LLC
Parkinson's Disease
A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants
The purpose of this study is to evaluate long-term safety of TVP-1012 (1 mg/day) with levodopa in Japanese participants with Parkinson's disease.
- Trial name
- NCT02337764
- Testing
- TVP-1012 1mg
- Where
- 24 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Takeda
Dementia, Alzheimer Disease
Efficacy Study of Kinto Care Coaching for Dementia Family Caregivers
The goal of this clinical trial is to evaluate Kinto's Care Coaching intervention for dementia caregivers. The main questions it aims to answer are: Does the intervention help caregivers to address their general caregiving goals…
- Conditions
- Dementia, Alzheimer Disease, Lewy Body Disease, Vascular Dementia
- Trial name
- NCT05916664
- Testing
- Kinto Care Coaching
- Where
- United States
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- Kinto
Parkinson Disease
A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease
This study is a fixed dose, dose response study to characterize the dose response for ropinirole PR in early stage PD patients (Hoehn \& Yahr stages I-III).
- Trial name
- TANDEM-662 (NCT01485172)
- Testing
- ropinirole monotherapy
- Where
- 34 sites in United States, Estonia and 3 more
- Volunteers
- 186 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease Dementia, Dementia With Lewy Bodies
ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)
This study is designed to evaluate the safety and treatment effects of fosgonimeton (ATH-1017) in subjects with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized treatment duration of 26 weeks.
- Trial name
- NCT04831281
- Testing
- ATH-1017
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- LeonaBio
Idiopathic Parkinson's Disease
Vercise Implantable Stimulator for Treating Parkinson's Disease
The purpose of this study is to document patient outcomes, including effectiveness, safety, and health economic data, for the Boston Scientific implantable deep brain stimulation (DBS) Vercise™ system for bilateral stimulation of…
- Trial name
- VANTAGE (NCT01221948)
- Testing
- Deep Brain Stimulation
- Where
- 7 sites in Austria, France and 4 more
- Volunteers
- 53 people
- Sponsor
- Boston Scientific Corporation
Dementia With Lewy Bodies
Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study
This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.
- Trial name
- NCT02669433
- Testing
- RVT-101 35 mg, RVT-101 70 mg
- Where
- 65 sites in United States, Canada and 5 more
- Volunteers
- 484 people
- Sponsor
- Axovant Sciences Ltd.
Parkinson's Disease
A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease
The primary objective of the study is to compare the adhesiveness of 2 different patch formulations of Rotigotine using the largest patch size of 40 cm^2, under the assumption that both patch formulations show similar…
- Trial name
- NCT02230904
- Testing
- Rotigotine (Test product PR 2.3.1), Rotigotine (Reference product PR 2.1.1)
- Where
- 11 sites in Germany
- Volunteers
- 57 people
- Sponsor
- UCB BIOSCIENCES GmbH
Parkinson Disease
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
This is a multicenter, randomized, three-arm, parallel-group, double-blind, placebo-controlled, study to evaluate the efficacy, safety and pharmacokinetics (PK) of pridopidine vs.
- Trial name
- NCT03922711
- Testing
- Pridopidine
- Where
- 33 sites in United States
- Volunteers
- 23 people
- Sponsor
- Prilenia
Parkinson's Disease
A Study of E2007 In Patients With Parkinson's Disease
Phase IIb open-label extension study for patients with Parkinson's Disease. All patients will receive active study drug. The study will involve outpatient visits only.
- Trial name
- NCT00427011
- Testing
- E2007
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eisai Inc.
Parkinson Disease
Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease
To investigate the efficacy and the safety of ropinirole PR/XR tablets to ropinirole immediate release (IR) tablets with advanced Parkinson's disease in conjunction with L-dopa in a double-blind, parallel group comparison study.
- Trial name
- NCT00823836
- Testing
- ropinirole PR/XR, ropinirole IR
- Where
- 54 sites in Japan
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced Parkinson's disease.
- Trial name
- NCT01130493
- Testing
- IPX066, CLE
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 110 people
- Sponsor
- Impax Laboratories, LLC
Lewy Body Disease, Parkinson Disease
A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9…
- Trial name
- NCT04764669
- Testing
- E2027
- Where
- 14 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Eisai Inc.
Parkinson Disease, Off Episodes
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to determine the efficacy, safety and…
- Trial name
- NCT02469090
- Testing
- APL-130277
- Where
- 33 sites in United States, Canada
- Volunteers
- 141 people
- Sponsor
- Sumitomo Pharma America, Inc.
Idiopathic Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.
- Trial name
- NCT00505687
- Testing
- Rotigotine
- Where
- 26 sites in United States, Austria and 6 more
- Volunteers
- 186 people
- Sponsor
- UCB Pharma
Parkinson's Disease
A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease
This study examines the efficacy of three doses of IPX066 as compared to placebo in Parkinson's disease.
- Trial name
- APEX-PD (NCT00880620)
- Testing
- IPX066 95 mg LD, IPX066 145 mg LD, IPX066 195 mg LD
- Where
- 60 sites in United States, Canada and 5 more
- Volunteers
- 381 people
- Sponsor
- Impax Laboratories, LLC
Parkinson's Disease
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
The purposes of the study are to determine: i. To assess the efficacy of Tigan® (trimethobenzamide) in preventing nausea and vomiting when initiating therapy with Apokyn® (apomorphine) ii.
- Trial name
- NCT00489255
- Testing
- Tigan®
- Where
- 27 sites in United States
- Volunteers
- 117 people
- Sponsor
- Ipsen
Parkinson's Disease
ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease
The proposed study will evaluate the safety, and initial efficacy of using the ExAblate Transcranial to create a unilateral lesion in the globus pallidus as an adjunct to PD medications in subjects who are over 30 years of age…
- Trial name
- NCT02263885
- Testing
- ExAblate Transcranial System
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- InSightec
Parkinson's Disease
Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study of E2007 in levodopa treated Parkinson's disease patients with motor fluctuations.
- Trial name
- NCT00368108
- Testing
- 2 mg perampanel, 4 mg perampanel
- Where
- 114 sites in United States, Canada
- Volunteers
- 752 people
- Sponsor
- Eisai Inc.